1263423-08-0

Basic information

• Product Name: 4-{6-chloro-8-[(2-methylpropyl)amino]imidazo[1,2-b]pyridazin-3-yl}-N-cyclopropylbenzamide
• Synonyms: 4-{6-chloro-8-[(2-methylpropyl)amino]imidazo[1,2-b]pyridazin-3-yl}-N-cyclopropylbenzamide
• CAS NO: 1263423-08-0
• Molecular Weight: 383.881
• Mol File: 1263423-08-0.mol

Chemical Properties

• CAS DataBase Reference: 4-{6-chloro-8-[(2-methylpropyl)amino]imidazo[1,2-b]pyridazin-3-yl}-N-cyclopropylbenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-{6-chloro-8-[(2-methylpropyl)amino]imidazo[1,2-b]pyridazin-3-yl}-N-cyclopropylbenzamide(1263423-08-0)
• EPA Substance Registry System: 4-{6-chloro-8-[(2-methylpropyl)amino]imidazo[1,2-b]pyridazin-3-yl}-N-cyclopropylbenzamide(1263423-08-0)

Safety Data

• Hazardous Substances Data: 1263423-08-0(Hazardous Substances Data)

Upstream product

• 933190-51-3 8-bromo-6-chloro-imidazo[1,2-b]pyridazine 
• 860173-33-7 4-(cyclopropylaminocarbonyl)phenylboronic acid pinacol ester 
• 1263425-60-0 6-chloro-3-iodo-N-(2-methylpropyl)imidazo[1,2-b]pyridazin-8-amine 
• 827614-68-6 N-cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide 
• 1263425-59-7 8-bromo-6-chloro-3-iodoimidazo[1,2-b]pyridazine 
• 933034-89-0 8-bromo-6-chloro-imidazo[1,2-b]pyridazine hydrochloride 
• 180516-87-4 4-carboxyphenylboronic acid pinacol ester 

Downstream Products

• 1263423-09-1 4-(6-(Cyclohexylamino)-8-(isobutylamino)imidazo[1,2-b]pyridazin-3-yl)-N-cyclopropylbenzamide 
• 1365238-96-5 N-cyclopropyl-4-{8-[(2-methylpropyl)amino]-6-(methylsulfanyl)imidazo[1,2-b]pyridazin-3-yl}benzamide 
• 1365238-07-8 C₂₈H₂₉N₅O₃ 
• 1365238-06-7 N-cyclopropyl-4-{8-[(2-methylpropyl)amino]imidazo[1,2-b]pyridazin-3-yl}benzamide 
• 1365239-03-7 N-cyclopropyl-4-{8-[(2-methylpropyl)amino]-6-(methylsulfonyl)imidazo[1,2-b]pyridazin-3-yl}benzamide 

Relevant articles and documents

FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION

Provided are a compound represented by general formula (1) and having a TTK inhibitory action and a medicine containing the compound. In formula (1), (X, Y, V, W) is (—N═, ═CR1—, ═N—, —CR7═), (—CR2═, ═N—, ═N—, —CR7═), etc.; A is an (un)substituted aromatic hydrocarbon ring, etc.; L is a single bond, —C(═O)—NRA—, etc.; Z is a group represented by the formula —NR3R4 or a group represented by the formula —OR5; R1 to R3, R6, and R7 each is a hydrogen atom, etc.; R4 and R5 each is an (un)substituted alkyl, etc.; and R8 is an (un)substituted cycloalkyl, etc.

SUBSTITUTED IMIDAZOPYRIDAZINES

The present invention relates to substituted imidazopyridazine compounds of general formula (l), which are Mps -1 (Monopolar Spindle 1) Kinase inhibitors (also known as Tyrosine Threonine Kinase, TTK) in which R3, R5, and A are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.